Rice bran protein peptide PVLWGVPKG alleviate gastric mucosal damage induced by Helicobacter pylori infection.
Rice bran protein peptide PVLWGVPKG—let’s call it PV9—just landed in the Helicobacter pylori research spotlight. A team out of Qiqihar University and Heilongjiang Bayi Agricultural University reports that this nine-amino-acid peptide can shield gastric mucosal cells from H. pylori-induced damage in vitro. If you’re deep into peptide research, this one is worth a closer look.
NPJ Sci Food
by Li G, Wang Q, Liu X et al.
“Rice bran protein peptide PVLWGVPKG alleviate gastric mucosal damage induced by Helicobacter pylori infection. Li G(1), Wang Q(1), Liu X(2), Miao Z(1), Wang Z(1), Zheng X(3). Author information: (1)Heilongjiang Provincial Key Laboratory of Corn Deep Processing Theory and Technology, College of Food and Bioengineering, Qiqihar University, Qiqihar, China. (2)Heilongjiang Provincial Key Laboratory of Corn Deep Processing Theory and Technology, College of Food and Bioengineering, Qiqihar University, Qiqihar, China. liuxiaolan001@126.com. (3)College of Food Science, Heilongjiang Bayi Agricultural University, Daqing, China. zhengxiqun@126.com. The aim of this study was to investigate the effect of PVLWGVPKG (PV9) on gastric mucosa cell damage induced by Helicobacter pylori infection. PV9 intervention could significantly reduce the number of Helicobacter pylori adhering to GES-1 cells (p <0.05). Molecular docking showed that PV9 and its degraded fragments could bind to Helicobacter pylori adhesins, and hydrogen bonds might be the main driving force. Dot blot assays confirmed the binding between PV9 and adhesins SabA and BabA in vitro. The protective mechanism of PV9 against Helicobacter pylori infection-induced GES-1 damage cells was analyzed. It was found that PV9 could accelerate the clearance of reactive oxygen species, reduce mitochondrial membrane potential, improve cell cycle arrest, and prevent apoptosis. In addition, PV9 can also significantly improve the antioxidant capacity of cells (SOD, GSH-Px, and CAT), reducing the content of pro-inflammatory factors (IL-1β, IL-6, IL-8, IL-18, and TNF-α) and increasing the content of anti-inflammatory factors (IL-10). The results of qRT-PCR showed that PV9 could protect GES-1 cells by regulating the expression of apoptotic factors. Moreover, the TLR4/MyD88/NF-κB signaling pathways may play a significant role in this process. This study provides a new idea for antagonizing Helicobacter pylori infection with active peptide components. © 2026. The Author(s). Conflict of interest statement: Competing interests: The authors declare no competing interests.”
Here’s what went down: PV9 slashed the number of H. pylori bacteria able to stick to GES-1 gastric cells. Molecular docking work suggests the peptide—and its breakdown products—binds directly to bacterial adhesins, specifically SabA and BabA. That’s not just computer modeling: dot blot assays confirmed the binding in a dish.
But the peptide didn’t stop at blocking adhesion. PV9 tackled the mess H. pylori leaves behind, including oxidative stress and inflammation. The researchers saw:
Faster clearance of reactive oxygen species
Improved antioxidant enzyme activity (SOD, GSH-Px, CAT)
Lower levels of pro-inflammatory factors (like IL-1β, IL-6, TNF-α)
Higher anti-inflammatory marker IL-10
Less cell cycle arrest and apoptosis
Evidence the TLR4/MyD88/NF-κB pathway is involved
Key takeaway: PV9 isn’t just sitting on the sidelines. It’s actively defending gastric cells on multiple fronts—blocking bacterial grip, calming inflammation, and boosting antioxidant defenses. That’s a big deal for anyone studying peptide interactions with pathogens.
The field of functional food peptides is wide open, and PV9 is another reminder that nature has plenty of potent sequences left to discover. For more on promising peptide candidates and where to source them, check the vendor directory. This is a space to watch.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.